Triumph Capital Management sells 364 shares of Johnson & Johnson (NYSE:JNJ)


Triumph Capital Management reduced its position in shares of Johnson & Johnson (NYSE:JNJGet a rating) by 15.9% in the first quarter, according to its latest filing with the Securities and Exchange Commission. The fund held 1,922 shares of the company after selling 364 shares during the quarter. Triumph Capital Management’s holdings in Johnson & Johnson were worth $341,000 when it last filed with the SEC.

A number of other institutional investors also bought and sold shares of the company. Magnolia Capital Management Ltd. increased its holding in Johnson & Johnson shares by 0.5% during the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company valued at $1,978,000 after buying 55 more shares last quarter. Howard Financial Services LTD. increased its holding in Johnson & Johnson shares by 2.1% in the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company valued at $489,000 after buying 57 more shares last quarter. American Financial Advisors LLC increased its holding in Johnson & Johnson shares by 2.1% in the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company valued at $481,000 after buying 57 more shares last quarter. Capital Investment Counsel Inc increased its stake in Johnson & Johnson shares by 0.8% during the 4th quarter. Capital Investment Counsel Inc. now owns 7,796 shares of the company valued at $1,334,000 after buying 59 additional shares in the last quarter. Finally, Kwmg LLC increased its stake in Johnson & Johnson by 2.6% during the first quarter. Kwmg LLC now owns 2,354 shares of the company worth $417,000 after acquiring 59 additional shares in the last quarter. Institutional investors hold 68.78% of the company’s shares.

Analysts set new price targets

JNJ has been the subject of several research reports. Goldman Sachs Group raised its price target on Johnson & Johnson shares from $163.00 to $181.00 and gave the stock a “neutral” rating in a Tuesday, April 12 research note. Raymond James raised his price target on Johnson & Johnson shares from $195.00 to $196.00 and gave the stock an “outperform” rating in a Wednesday, April 20 research note. Morgan Stanley raised its price target on Johnson & Johnson shares from $173.00 to $174.00 and gave the stock an “equal weight” rating in a Friday, July 8 research note. SVB Leerink lowered its price target on Johnson & Johnson shares from $200.00 to $194.00 in a Wednesday July 20 research note. Finally, UBS Group lowered its price target on Johnson & Johnson shares from $185.00 to $180.00 in a Thursday, July 21 research note. Four equity research analysts gave the stock a hold rating, five gave the stock a buy rating and one gave the stock a strong buy rating. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.89.

Insider Buying and Selling at Johnson & Johnson

In other news from Johnson & Johnson, CAD Robert J. Decker sold 8,462 shares of the company in a transaction that took place on Thursday, May 26. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a filing with the SEC, accessible via this link. In other Johnson & Johnson news, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a trade that took place Friday, June 10. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company, valued at $12,336,803. The sale was disclosed in a filing with the SEC, accessible via this link. Additionally, CAO Robert J. Decker sold 8,462 shares of the company in a trade that took place on Thursday, May 26. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company, valued at $2,785,140. Disclosure of this sale can be found here. 0.35% of the shares are held by insiders.

Johnson & Johnson Stock up 0.2%

JNJ opened at $174.52 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt ratio of 0.39. The company has a 50-day moving average price of $175.95 and a 200-day moving average price of $174.46. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The stock has a market capitalization of $459.23 billion, a price/earnings ratio of 25.40, a PEG ratio of 3.28 and a beta of 0.63.

Johnson & Johnson (NYSE:JNJGet a rating) last released its quarterly earnings data on Tuesday, July 19. The company reported earnings per share of $2.59 for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company posted revenue of $24.02 billion in the quarter, compared to $23.85 billion expected by analysts. In the same period a year earlier, the company earned earnings per share of $2.48. The company’s quarterly revenue increased 3.0% year over year. Equity research analysts expect Johnson & Johnson to post earnings per share of 10.05 for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13 per share. The ex-dividend date is Monday, August 22. This represents a dividend of $4.52 on an annualized basis and a yield of 2.59%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Johnson & Johnson Company Profile

(Get a rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Featured articles

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.

Comments are closed.